| Identification | Back Directory | [Name]
Ganciclovir sodium | [CAS]
107910-75-8 | [Synonyms]
Rs 21592 sodium
Unii-02L083W284
GANCICLOVIR SODIUM
Sodium Ganciclovir
Cytovene IV sodium
Gancyclovir sodium
Ganciclovir Impurity 7
Ganciclovir Sodium Salt
Ganciclovir sodium, >=98%
Ganciclovir monosodium salt
Ganciclovir sodium###Bw 759u
Ganciclovir sodium USP/EP/BP
Ganciclovir sodium (API)
sodium 2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-6-purin-1-idone
9-[[1-(Hydroxymethyl)-2-hydroxyethoxy]methyl]-2-amino-9H-purine-6(1H)-one/sodium,(1:1) salt
2-amino-1,9-dihydro-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-6h-purin-6-one sodium salt
6H-Purin-6-one, 1,9-dihydro-2-amino-9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-, monosodium salt
6H-Purin-6-one, 2-amino-1,9-dihydro-9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-, monosodium salt | [EINECS(EC#)]
641-368-8 | [Molecular Formula]
C9H12N5NaO4 | [MDL Number]
MFCD00873979 | [MOL File]
107910-75-8.mol | [Molecular Weight]
277.21 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at 4°C, protect from light | [solubility ]
DMSO: 5 mg/mL (17.91 mM) | [form ]
Solid | [color ]
White to off-white | [Water Solubility ]
Water: 50 mg/mL (179.06 mM) | [InChI]
InChI=1S/C9H13N5O4.Na.H/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16;;/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17);; | [InChIKey]
HKZYYRUGZQKKFS-UHFFFAOYSA-N | [SMILES]
C(N1C=NC2C(NC(N)=NC1=2)=O)OC(CO)CO.[NaH] |
| Hazard Information | Back Directory | [Uses]
Ganciclovir Sodium Salt is an inhibitor of the Herpesvirus family. It can be used in analytical study of establishment of a Raman database for non-invasive and rapid screening of liquid injectables. | [Brand name]
Cytovene (Roche). | [in vivo]
Ganciclovir (BW 759) (50 mg/kg; i.p.; twice a day for five injections) significantly decreases white blood cells, red blood cells and platelets in newborn mice, and can diffuse into the brain and the perilymphatic space of the inner ear[3].
Ganciclovir (1-80 mg/kg; i.h.; daily for 5 days) delays murine cytomegalovirus (MCMV)-induced wasting syndrome and mortality[6]. | Animal Model: | Non-inbred Oncins France 1 (OF1) mice and albino rats non-immunized for
MCMV[3] | | Dosage: | 50 mg/kg | | Administration: | Intraperitoneal injection, twice a day for five injections (mice) or 3 days (adult rats) (Pharmacokinetic Study) | | Result: | In adult rats, the intracochlear diffusion of Ganciclovir was shown to achieve the same concentration as in blood. In gestating mice, transplacental diffusion was observed, with a fetal-to-maternal blood ratio of 0.5. In newborn mice, the plasma concentration profile of Ganciclovir showed a peak at 2 h followed by a gradual decrease. In adult mice, the concentration peaked at 1 h, but became undetectable by 2 h after injection.
Significantly decreased white blood cells, red blood cells and platelets in newborn mice.
|
| Animal Model: | Female SCID mice inoculated with MCMV[6] | | Dosage: | 0, 1, 10, 80 and 160 mg/kg | | Administration: | Subcutaneous injection, once daily for 5 days | | Result: | Dose dependently delayed the wasting syndrome and mortality in a dose range up to 80 mg/kg per day, whereas a dose of 160 mg/kg per day induced reversible side-effects. |
| [IC 50]
CMV; HSV-1; HSV-2; FHV-1: 5.2 μM (IC50) |
|
| Company Name: |
Jia Xing Isenchem Co.,Ltd
|
| Telephone: |
0573-85285100 18627885956 |
| Website: |
https://www.chemicalbook.com/ShowSupplierProductsList14265/0_EN.htm |
|